UPCC 09317: A Phase 1b/2a Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent/Metastatic Human Papilloma Virus Associated Head and Neck Squamous Cancer
-
- STATUS
- None
Updated on 19 February 2024
Summary
The main purpose of this study is to measure how well and how safe MEDI0457 vaccine in combination with Durvalumab is in treating patients with recurrent/metastatic human papilloma virus associated head and neck squamous cancer.
Details
| Condition | TBD, tbd, tbd |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | 03162224 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.